5 challenges that governments need to address in resolving the stagnation in antibiotic development

  30 September 2022

We are now well into a third decade of failure and standstill in developing new antibiotics. Meanwhile resistance to all of our existing antibiotics continues to develop across the world and antibiotic resistance was the cause of 1.2 million deaths in 2019, more than for HIV/AIDS and malaria. The traditional market-based financing model for research and development of new antibiotics continues to fail. The reason for the lack of innovation is often presented as a matter of insufficient profitability for the pharmaceutical industry. However, there are significant scientific challenges that remain unresolved, which contributed to large pharmaceutical companies abandoning the field over the past decades.

Further reading: ReAct
Author(s): ReAct
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!